Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience

Published:2009-12-01 Issue:6 Volume:53 Page:1029-1034
ISSN:1545-5009
Container-title:Pediatric Blood & Cancer
language:en
Short-container-title:Pediatr. Blood Cancer

Author:

Casey Denise A.,Wexler Leonard H.,Merchant Melinda S.,Chou Alexander J.,Merola Pamela R.,Price Anita P.,Meyers Paul A.

Publisher

Wiley

Subject

Oncology,Hematology,Pediatrics, Perinatology and Child Health

Reference44 articles.

1. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades;Esiashvili;J Pediatr Hematol Oncol,2008

2. Ewing sarcoma: Historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future;Ludwig;Curr Opin Oncol,2008

3. Prognostic factors for patients with Ewing sarcoma at first recurrence following multi-modality therapy: A report from the Children's Oncology Group;Leavey;Pediatr Blood Cancer,2008

4. Improving outcomes after relapse in Ewing's Sarcoma: Analysis of 114 patients from a single institution;McTiernan;Sarcoma,2006

5. Therapy and survival after recurrence of Ewing's tumors: The Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997;Bacci;Ann Oncol,2003

Cited by 159 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615);European Journal of Cancer;2024-09

2. Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board;Cancer;2024-08-25

3. Co-targeting JAK1/STAT6/GAS6/TAM signaling improves chemotherapy efficacy in Ewing sarcoma;Nature Communications;2024-06-21

4. The Capacity of Drug-Metabolising Enzymes in Modulating the Therapeutic Efficacy of Drugs to Treat Rhabdomyosarcoma;Cancers;2024-02-29

5. Revisiting Temozolomide's role in solid tumors: Old is gold?;Journal of Cancer;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3